Four rituximab infusions,
does it really help with Reduced treatment failure in steroid-unresponsive adult ITP?
research showsThe grade is D with 30 points. Among 109 analyzed participants, treatment failure occurred in 32/55 (58%) with rituximab and 37/54 (69%) with placebo; HR 0.89 (95% CI 0.55 to 1.45), P=0.65. The raw absolute difference was -10.3 percentage points.
ads claimVerdict 2726 is C with 50 points for eltrombopag, verdict 2766 is C with 54 points for romiplostim, and verdict 2776 is C with 50 points for fostamatinib. The first two are TPO-receptor agonists, fostamatinib inhibits SYK, and rituximab targets CD20. These are different second-line mechanisms, and only this verdict was null on primary treatment failure.
Useful facts when choosing a product
- Rituximab is an anti-CD20 B-cell antibody.
- The trial was double-blind and placebo-controlled.
- Adult ITP second-line treatment spans different mechanisms.
What the research actually shows
This 14-center double-blind placebo-controlled trial enrolled 112 and analyzed 109 participants, 55 versus 54, over 78 weeks. Enrollment below 200 was the named limitation. Public support from the South-East Regional Health Authority and Østfold Hospital was mixed with Roche France and Norway support; authors disclosed Roche research funding and honoraria.
Why this is classified as D (30)
One small placebo-controlled trial was null on clinical treatment failure and left substantial benefit possible, giving D with 30 points.
Counterpoint. A null average strategy result does not prove zero response in every patient.
Rejudgment record. Cross-check applied — Cross-checked the RITP report, registration, acknowledgments, and disclosures for endpoint definition, HR and CI, placebo blinding, and mixed funding
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced treatment failure | D | HR 0.89 (95% CI 0.55 to 1.45) was null. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | 14-center double-blind placebo-controlled randomized trial | 54 | South-East Regional Health Authority, Østfold Hospital, Roche France, and Roche Norway | Treatment failure: splenectomy or meeting prespecified splenectomy criteria from week 12 | 32/55 versus 37/54; HR 0.89 (95% CI 0.55 to 1.45), P=0.65; absolute -10.3 points | Pivotal single mixed-funded trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Rituximab as Second-Line Treatment for Adult ITP - Null — Evidence Grade D·30. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/rituximab-second-line-adult-itp-treatment-failure/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.